Greg Berk

Greg Berk has a diverse work experience in the field of medical and biopharmaceuticals. Greg is currently serving as the Chief Medical Officer at Allorion Therapeutics since January 2023. Prior to that, they served as a Board Member at Beyond Cancer, Ltd. and held the role of Board Member, co-founder, and part-time at XLINK Therapeutics. In September 2020, they joined Inflection Biosciences Ltd as a Board Member, and their tenure ended in June 2023. From April 2021 to December 2022, they worked at GT Biopharma as the President of Research & Development and Chief Medical Officer. Greg also served as a Board Member at GT Biopharma, Inc. from November 2020 to April 2021. Previously, they held the position of Chief Medical Officer at Celularity from December 2020 to April 2021. Before that, they worked as a Hematology-Oncology Consultant at Gregory Berk, MD, PC from February 2017 to December 2020. Greg has also served as the Chief Medical Officer at Verastem from April 2016 to January 2017 and as the President and Chief Medical Officer at Sideris Pharmaceuticals from January 2014 to February 2016.

Greg Berk began their education journey at Tulane University from 1976 to 1980, where they earned a Bachelor of Science degree in biochemistry with summa cum laude honors. Greg then pursued their Doctor of Medicine (MD) degree at Case Western Reserve University School of Medicine from 1980 to 1984. Continuing their medical education, Greg Berk attended the Joan & Sanford I. Weill Medical College of Cornell University from 1984 to 1990, where they obtained their Doctor of Medicine (MD) degree specializing in Internal Medicine and Heme-Onc. Additional certifications in internal medicine and medical oncology from ABIM were obtained by Greg Berk at an undisclosed institution and year.